This signaling could be via downstream dysregulation of NE-associated transcription factors (12, 15, 16) or by abrogating the cell-cycle progression seen in other cancer types (21, 62, 63), with differential effects influenced by underlying RB1 and TP53 loss. The gene discussed is TP53; the disease is cancer.